申请人:GALDERMA RESEARCH & DEVELOPMENT
公开号:US10246422B2
公开(公告)日:2019-04-02
The invention relates to novel heterocyclic compounds of general formula (I), as well as their pharmaceutically acceptable salts, and their enantiomers. The invention also relates to the use thereof as a medicinal product, preferably in the prevention and/or treatment of inflammatory diseases with a neurogenic component or use thereof as a cosmetic. The compounds of the present invention act as antagonists of the CGRP-R receptor.
本发明涉及通式(I)的新型杂环化合物及其药学上可接受的盐类,以及它们的对映体。本发明还涉及其作为医药产品的用途,优选用于预防和/或治疗具有神经源成分的炎症性疾病,或用作化妆品。本发明的化合物可作为 CGRP-R 受体的拮抗剂。